Last reviewed · How we verify
sinemet plus
Sinemet Plus combines levodopa (a dopamine precursor) with carbidopa (a decarboxylase inhibitor) and entacapone (a COMT inhibitor) to increase dopamine availability in the brain for Parkinson's disease treatment.
Sinemet Plus combines levodopa (a dopamine precursor) with carbidopa (a decarboxylase inhibitor) and entacapone (a COMT inhibitor) to increase dopamine availability in the brain for Parkinson's disease treatment. Used for Parkinson's disease with motor fluctuations.
At a glance
| Generic name | sinemet plus |
|---|---|
| Also known as | sinemet group |
| Sponsor | Hospital de Granollers |
| Drug class | Dopamine replacement therapy with COMT inhibitor |
| Target | Dopamine pathway; COMT enzyme |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Levodopa crosses the blood-brain barrier and is converted to dopamine, replacing depleted dopamine in Parkinson's patients. Carbidopa inhibits peripheral conversion of levodopa to dopamine, allowing more levodopa to reach the brain. Entacapone inhibits catechol-O-methyltransferase (COMT), an enzyme that breaks down dopamine, thereby extending dopamine's duration of action and reducing motor fluctuations.
Approved indications
- Parkinson's disease with motor fluctuations
Common side effects
- Dyskinesia
- Nausea
- Dizziness
- Orthostatic hypotension
- Abdominal pain
- Diarrhea
Key clinical trials
- Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease (PHASE2)
- Montelukast in Parkinson Disease (PHASE2, PHASE3)
- Dopaminergic Dysfunction in Late-Life Depression (PHASE2)
- Dopaminergic Therapy for Anhedonia - 2 (PHASE4)
- Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease
- Fexofenadine as Adjuvant Therapy in Parkinson Disease (PHASE2, PHASE3)
- Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm (PHASE1, PHASE2)
- Vinpocetine in Patients With Parkinsonian Disease (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sinemet plus CI brief — competitive landscape report
- sinemet plus updates RSS · CI watch RSS
- Hospital de Granollers portfolio CI